CSF1R mosaicism in a family with hereditary diffuse leukoencephalopathy with spheroids by Eichler, Florian S. et al.
REPORT
CSF1R mosaicism in a family with hereditary
diffuse leukoencephalopathy with spheroids
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Mutations in the colony stimulating factor 1 receptor (CSF1R) have recently been discovered as causal for hereditary diffuse leukoen-
cephalopathy with axonal spheroids. We identified a novel, heterozygous missense mutation in CSF1R [c.1990G4A p.(E664K)] by
exome sequencing in five members of a family with hereditary diffuse leukoencephalopathy with axonal spheroids. Three affected
siblings had characteristic white matter abnormalities and presented with progressive neurological decline. In the fourth affected sibling,
early progression halted after allogeneic haematopoietic stem cell transplantation from a related donor. Blood spot DNA from this
subject displayed chimerism in CSF1R acquired after haematopoietic stem cell transplantation. Interestingly, both parents were un-
affected but the mother’s blood and saliva were mosaic for the CSF1R mutation. Our findings suggest that expression of wild-type
CSF1R in some cells, whether achieved by mosaicism or chimerism, may confer benefit in hereditary diffuse leukoencephalopathy with
axonal spheroids and suggest that haematopoietic stem cell transplantation might have a therapeutic role for this disorder.
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Introduction
Leukodystrophies are inherited disorders affecting the white
matter of the CNS. While most disorders have predomin-
antly glial cell or myelin sheath abnormalities, some dis-
orders include significant axonal pathology. Hereditary
diffuse leukoencephalopathy with axonal spheroids
(HDLS) is a progressive autosomal dominant leukodystro-
phy with an onset typically occurring in the fourth or fifth
decade of life. Recently, Rademakers and colleagues (2012)
identified mutations in CSF1R, encoding colony stimulating
factor 1, as the cause of HDLS.
We performed exome sequencing in a family with four
siblings affected by an unknown adult-onset leukoencepha-
lopathy and found a novel heterozygous mutation in
CSF1R. This was particularly surprising as the parents
were unaffected, suggesting an autosomal recessive dis-
order. One of the four siblings carried the presumed diag-
nosis of metachromatic leukodystrophy and had stabilized
after haematopoietic stem cell transplantation 15 years
earlier.
Materials and methods
Human subjects
Ethical approval was obtained from Massachusetts General
Hospital (protocol #2007P002248). Informed consent was ob-
tained from all subjects. Epstein-Barr virus transformed
lymphoblast cell lines were established in all subjects. DNA
was subsequently extracted from whole blood and/or lympho-
blast cell lines and from saliva and buccal swabs from sus-
pected family members with mosaicism or chimerism of
CSF1R.
The brain MRI in all affected siblings was consistent with a
leukodystrophy, i.e. symmetrical, confluent, hyperintense
signal on T2-weighted images and prominent T1 hypointensity
of the affected white matter relative to grey matter structures.
Brain tissue was not available.
Case histories
Patient II-1
This female patient developed behavioural and memory diffi-
culties at 35 years of age. She was described as impulsive and
was noted to frequently yell and shout insults. Once, she was
found disoriented outside her home. Around the same time,
she developed gait difficulties, described as shuffling gait with
balance problems. By 36 years of age, she was wheelchair-
bound and no longer able to ambulate. She was diagnosed
with presumed adult-onset metachromatic leukodystrophy
and a year later received an allogeneic haematopoietic stem
cell transplantation (HSCT); her unaffected brother (Patient
II-5) was the donor. She successfully engrafted and her disease
stabilized within 6 months from the transplant. For the next
15 years she maintained stable language function and person-
ality and remained non-ambulatory.
Patient II-2
A 56-year-old male developed confusion and word-finding dif-
ficulties. Over the next 2 years, he experienced gait difficulties
and required a walker. Around the same time, he developed a
seizure disorder, with seizures occurring several times per
month. At the present time, expressive language has deterio-
rated, but he understands simple commands. He can get quite
aggressive and, on occasion, punch and spit at his caregivers.
He does not verbalize spontaneously and is no longer able to
ambulate. Testing for arylsulphatase A enzyme abnormalities
was negative. No sulphatides in urine were present.
Patient II-3
A 54-year-old female with a history of psychological problems
began having gait difficulties. Her parents noted that she was
shuffling and had difficulties walking up stairs. She also
became more depressed and tearful. She had a seizure-like
event and was placed on gabapentin. After being unable to
walk, she was placed in a long-term care facility. Testing for
arylsulphatase A enzyme abnormalities was negative. No sul-
phatides in urine were present.
Patient II-4
A 55-year-old female began having behavioural difficulties, de-
pression, and psychotic episodes. Soon after these first symp-
toms she developed gait difficulties and needed full-time
assistance. Due to swallowing problems, she required place-
ment of a gastric tube. At 58 years of age, she was admitted
to a nursing home following a hospital admission for status
epilepticus. On assessment 2 years later, she was non-verbal
and non-ambulatory. She grunted and grimaced to pain, but
showed no interactions with her surroundings otherwise. She
passed away at 60 years of age.
Parents and unaffected siblings
The mother (Patient I-2) is an 83-year-old homemaker with
intact cognition, speech and motor abilities. The father
(Patient I-1) is an 85-year-old retired tool maker and machin-
ist. Neurological examination on parents and unaffected sib-
lings is normal.
Exome sequencing and Sanger
sequencing
Exome sequencing of blood DNA was performed in five family
members: two affected siblings (Patients II-2 and II-3), one
unaffected sibling (Patient II-6) and both parents (Patients I-1
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and I-2). A recessive mode of inheritance was assumed, as both
parents were unaffected.
A solution hybrid method was used to enrich for DNA tar-
geting the exome (Agilent Sure-Select Human All exon 50Mb),
and sequencing was performed on the Illumina HiSeq2000
using 90-bp paired-end reads.
Unaligned Illumina reads were processed through the Broad
Institute Picard suite pipeline and mapped to the hg19 refer-
ence genome using the Burrows-Wheeler alignment (BWA) al-
gorithm (Li and Durbin, 2009). High quality indel and single
nucleotide variant calling and annotation were performed
using the Broad GATK2 joint analysis pipeline using standard
filtering criteria (read depth510%, genotype quality
score530). Details of solution hybrid selection and target se-
quence coverage are presented in Supplementary Table 1. We
prioritized novel variants by excluding single nucleotide poly-
morphisms (SNPs) present in whole genome sequencing data
from 1092 individuals (1000 Genomes Project Consortium et
al., 2012) or in dbSNP (Sherry et al., 2001). Any known
pathogenic mutations found in dbSNP were filtered out and
were included in further analysis.
Sanger sequencing of a 407-bp amplicon encompassing the mu-
tation was performed to confirm the CSF1R mutation in all
exome-sequenced subjects and to test for segregation of the variant
with disease in the family. Polymerase chain reaction (PCR) was
performed in a 25 ml volume with 40–50ng DNA, 1 ml of 10mM
forward primer 5’ TTCATGAGCCATCCAACC3’and reverse
primer 5’AGGCACAAGGAAACTTGCTC3’. Amplification condi-
tions were 95 C for 5min followed by 35 cycles at 95 C for 30s,
60 C for 30s, 72 C for 1min and final extension at 72 C for
10min. PCR amplification was followed by Sanger sequencing on
an ABI 3170 sequencer. PCR amplification and Sanger sequencing
was also performed using DNA extracted from saliva and lympho-
blastoid cell lines for two of the subjects. Mosaicism for the CSF1R
c.1990G=/>A, p.(E664K) mutation in DNA from the mother’s
blood was confirmed by cloning of a 2481-bp PCR product
(amplified using forward primer 5’CAAGCAG
GAACATGCTCTCA 3’ and reverse primer 5’TGGCTAC
TTCCCATGACACA3’) encompassing the mutation into vector
pGL3 (Promega) in 5’-3’ orientation using a naturally occurring
BamHI site. Sanger sequencing of six clones was performed using
the 5’TTCATGAGCCATCCAACC3’ primer.
For chimerism analyses, DNA isolated from donor blood,
recipient (post-transplant saliva and buccal swab), and post-
transplant blood samples were PCR amplified for 15 microsat-
ellite markers and amelogenin and analysed by fluorescent ca-
pillary electrophoresis (University of North Carolina).
Results
Affected siblings had characteristic white matter abnormal-
ities and presented with progressive neurologic decline.
Clinical characteristics are listed in Table 1. In one affected
sibling (Patient II-1), early progression halted after allogen-
eic HSCT from her unaffected brother (Patient II-5) 15
years ago. Representative MRI findings are shown in Fig. 1.
To identify the underlying causal gene, we targeted445
million base pairs in 157 523 exons from 15 994 genes for
exome sequencing in five family members (parents, affected
siblings Patients II-2 and II-3 and unaffected sibling Patient
II-6), with each targeted base covered on average 51 times
per individual (Supplementary Table 1). For each partici-
pant, 872 novel protein-altering variants were found, of
which 837 were missense mutations. To find causal mu-
tations inherited in an autosomal recessive manner, we
searched for genes with novel, deleterious mutations or
known recessive pathogenic mutations from dbSNP present
in both alleles in both affected siblings (either homozygous
or compound-heterozygous mutations) but with only one
of the two deleterious mutations in the father and the other
in the mother, and at most one deleterious mutation in the
unaffected sibling. No such genes or variants were found.
We did identify a novel heterozygous G to A transition
within exon 15 of CSF1R (c.1990G4A) in both affected
siblings (49% of exome sequencing reads in Patient II-2
and 40% of sequencing reads in Patient II-3) that was
absent in the sequences from the unaffected sibling and
the father (Supplementary Table 1). The A allele is also
absent in the dbSNP database (Sherry et al., 2001), in
2184 chromosomes from the 1KGP (1000 Genomes
Project Consortium et al., 2012), in 13 006 exome se-
quences from the National Heart Lung and Blood
Institute’s Exome Sequencing Project [Exome Variant
Server, NHLBI Exome Sequencing Project (ESP), Seattle,
WA (URL:http://evs.gs.washington.edu/EVS/) (8 June
2013)] and in the ExAC database of 60 706 unrelated in-
dividuals [Exome Aggregation Consortium (ExAC),
Cambridge, MA (URL: http://exac.broadinstitute.org) (ac-
cessed 9 July 2015)]. The resulting non-synonymous
amino acid substitution, p.(E664K), is predicted to be
Table 1 Clinical characteristics and CSF1R mutation in family with HDLS
ID CSF1R
p.E664K
Sex Onset
age
Death
age
Initial
symptom
Clinical features during course of disease development
Behavioural Dementia Depression Parkinsonism Seizures
I-2 Mosaic F . Alive Healthy None None None None None
II-1 Chimeric F 35 Alive Impulsivity + + Not described Not described Not described
II-2 Heterozygous M 56 Alive Confusion + + + + + + Rigidity +
II-3 Heterozygous F 54 60 OCD + + + + + + + Not described +
II-4 Heterozygous F 55 60 Depression + + + + + + + + + (status)
OCD = obsessive compulsive disorder.
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deleterious by prediction algorithms PolyPhen-2 (Adzhubei
et al., 2013), SIFT (Kumar et al., 2009), MutationTaster
(Schwarz et al., 2010), and CADD (score of 36, ranking in
the 0.025 percentile of deleterious mutations) (Kircher et
al., 2014) and alters a site conserved across Euteleostomi
species (NCBI Resource Coordinators, 2013) and across
other CSF1/PDGF receptor family members (Fig. 2). As
this residue is predicted to lie within the tyrosine kinase
domain of CSF1R (Coussens et al., 1986), encoded by a
gene implicated previously in HDLS, a familial neurodegen-
erative condition with a similar phenotype (Rademakers et
al., 2012), we examined this variant more closely in all
family members.
Sanger sequencing at the novel CSFR1 mutation site
p.(E664K) confirmed exome variant calls in all samples,
and revealed that the mutation segregated with disease in
affected siblings (Fig. 3). The proportion of mutant A allele
for affected siblings was estimated at 50% from Sanger
sequencing of DNA from saliva (Patients II-1 and II-4) or
from blood (Patients II-2 and II-3; Fig. 3). While the father
(Patient I-1) did not carry the mutant A allele, DNA from
the blood and saliva of the unaffected mother (Patient I-2)
displayed mosaicism, with the A allele fraction of DNA
estimated at 15–20% from Sanger sequencing of saliva
or blood DNA and 20% from exome sequencing of blood
DNA (Fig. 3 and Supplementary Fig. 1). Based on the
Sanger sequence traces, the fraction of cells carrying the
mutant A allele appeared to be greater in DNA from
saliva (20% A allele; mixture of epithelial and
haematopoietic cells) than from the blood (15% A
allele; haematopoietic cells only), providing suggestive evi-
dence that mosaicism may differ by cell type (Fig. 3).
Sequencing of six subclones from the PCR product derived
from the mother’s blood DNA revealed one clone with the
mutant A allele and five clones with the wild-type G allele
(Supplementary Fig. 1). Chimerism analysis was performed
for affected sibling Patient II-1 using blood spot DNA ob-
tained415 years after HSCT. The per cent donor chimer-
ism, calculated from the average of 11 informative short
tandem repeat markers, was 15% (standard deviation 5%).
Discussion
Heterozygous mutations in CSF1R causing HDLS were first
identified by Rademakers et al. (2012). CSF1R encodes a
tyrosine kinase growth factor receptor for colony stimulat-
ing factor 1, the macrophage and monocyte-specific growth
factor (Ridge et al., 1990). This cell-surface receptor regu-
lates survival, proliferation, and differentiation of mononu-
clear phagocytic cells, including microglia of the CNS
(Stanley et al., 1997). In the brain, CSF1R protein is pre-
dominantly expressed in microglial cells (Ginhoux et al.,
2010), although low levels of CSF1R have been reported
in cultured neurons (Akiyama et al., 1994; Raivich et al.,
1998; Wang et al., 1999). All disease-causing mutations to
date—including that of our family—are located within the
tyrosine kinase domain of CSF1R.
Figure 1 MRI findings in HDLS. Affected sibling Patient II-2: 60-year-old male with progressive cognitive deterioration and motor problems.
His MRI shows enlarged ventricles with diffuse patchy white matter lesions more prominent in the frontal (A, white arrows) than in the posterior
regions (B, black arrows). There is no contrast enhancement present.
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The phenotype of HDLS is characterized by adult-onset
rapidly progressive neurodegenerative disease characterized
by behavioural, cognitive and motor changes. Our patients
followed this course and—with the exception of the trans-
planted patient—were all non-verbal or dead within 10
years of symptom onset. Brain imaging showed patchy in-
volvement of white matter, predominantly in the frontal
and parietal regions. The disorder is inherited in an auto-
somal dominant manner, and therefore affected individuals
would typically be expected to have an affected parent. In
our family, however, the mother was mosaic and un-
affected, conveying the false impression of a recessive pedi-
gree and indicating that the proportion of her cells with a
mutant allele was insufficient to precipitate a dementia
phenotype. Alternatively her asymptomatic state could
have represented a lack of penetrance or a late onset of
phenotype that so far had not manifested in the 83-year-
old female. A limitation of the study is that we did not have
access to post-mortem tissue to verify HDLS pathology or
mosaic status in various tissues.
Mosaic forms have been reported in other autosomal
dominant disorders, such as neurofibromatosis 1 and her-
editary haemorrhagic telangiectasia (Ruggieri and Huson,
2001; Lee et al., 2011). Some patients with mosaicism have
affected children, while others appear unable to pass the
mutation on to offspring, suggesting that the mutation can
be limited to a part of the soma and thus absent in the
germ line.
No treatment is currently known to halt or alter the
course of HDLS. Most patients reported to date succumb
to the disease within 10 years of symptom onset
(Rademakers et al., 2012). To have a patient retain a
high level of communication and survive beyond 15 years
after symptom onset is unusual and suggests amelioration
following HSCT. An individual who has undergone a suc-
cessful allogeneic bone marrow transplant is chimeric, i.e.
an individual comprised of multiple cell lineages derived
from distinct fertilized eggs (Biesecker and Spinner, 2013).
Chimerism is thus distinct from the related phenomenon of
mosaicism but either chimeric or mosaic status that lowers
the overall fraction of haematopoietic cells with mutant
CSF1R alleles can be of benefit.
Only a few neurological disorders are known to benefit
from HSCT. Among these are other leukodystrophies such
as adrenoleukodystrophy, metachromatic leukodystrophy,
and globoid cell leukodystrophy. All of these are recessive
disorders that require both alleles to be defective for disease
to occur. In contrast, HDLS is a dominant disorder where
one mutant allele alone can compromise CSF1R function,
with haploinsufficiency a likely cause (Konno et al., 2014).
HSCT may confer benefit in recessive disorders through
non-cell autonomous introduction of wild-type protein,
and may similarly enhance CSF1R signalling after partial
loss in HDLS. Only a small percentage of cells were found
to be corrected in the affected sibling 15 years after HSCT
(15%). However, the clinical benefit of HSCT with this
Human CSF1R wt ..VLVITEYCCYG..
Human CSF1R mutant  ..VLVITKYCCYG..
Human Kit           ..TLVITEYCCYG..
Human FLT3          ..IYLIFEYCCYG..
Human PDGFRα        ..IYIITEYCFYG..
Human PDGFRβ        ..IYIITEYCRYG..
Mouse CSF1R         ..VLVITEYCCYG..
Chicken CSF1R       ..ILVITEYCRYG..
Zebrafish CSF1R     ..VLVITEYCCHG..'
A
B
C
D
E
Figure 2 Genomic and protein localization of novel CSF1Rmutation. (A) Genomic organization of the 60 kb CSF1R gene with 22 exons
(vertical hatches); (B) exon structure of the human CSF1R cDNA, with start codon (ATG) and stop codon (TGA) shown. Arrow shows position
of c.1990G4A, p.(E664K) mutation in exon 15. (C) Domain structure of the CSF1R protein showing the immunoglobulin domains (Ig) and the
protein tyrosine kinase domain (PTK), interrupted by the kinase insert at amino acid positions 670-740 (shaded). (D) The position of the p.E664K
mutation adjacent to the kinase insert within the PTK domain. (E) Alignment for the parts of the PTK domain surrounding p.E664K, including
human CSF1/PDGF receptor family members and multiple CSF1R homologues.
1670 | BRAIN 2016: 139; 1666–1672 F. S. Eichler et al.
small percentage of corrected cells is consistent with per
cent correction seen after cell-based correction in the leu-
kodystrophies. In particular, cerebral childhood adrenoleu-
kodystrophy is known to stabilize after correction of only
20% of peripheral blood cells. We were not able to obtain
interim assessments of levels of chimerism after transplant
to determine the stability of chimerism levels over time. It is
possible that stabilization occurred spontaneously in our
transplanted patient and is not related to the HSCT. In
that case the correction of her peripheral blood cells was
coincidental to her clinical course. Late onset phenotypes
are known to show variability in course, and we can there-
fore not exclude this possibility but find it highly unlikely
given the immediately preceding precipitous decline.
While introduction of cells with wild-type CSF1R by
HSCT may compensate for partial loss of CSF1R function,
the alternative of over-expression of CSF1R beyond normal
levels in individual cells, by gene therapy for example, may
carry risks. An increase in CSF1R copy number and point
mutations leading to constitutive activation of the CSF1R
receptor has been associated with tumour development,
including haematological malignancies and renal cell car-
cinomas (Ridge et al., 1990; Soares et al., 2009).
In summary, this first report of mosaicism in CSF1R in a
family affected by HDLS, involving a mosaic unaffected
mother who passed the pathogenic mutation through her
germ line to multiple children, one of whom was chimeric
and showed a milder course, suggests strongly that HSCT
be explored for potential therapeutic benefit in this devas-
tating disorder.
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